VI
FOLD

Versor Investments’s Amicus Therapeutics FOLD Stock Holding History

Versor Investments’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.97M Sell
136,069
-735,165
-84% -$10.5M 4.82% 7
2025
Q4 		$12.4M Buy
+871,234
New +$8.56M 1.93% 7

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Versor Investments's FOLD Position: Q1 2026 in Review

Versor Investments reduced its Amicus Therapeutics (FOLD) stake by 84% in Q1 2026, selling an estimated $10.5M and leaving 136,069 shares worth $1.97M. The position accounts for 4.82% of the portfolio, ranked #7.

Versor Investments first reported a position in FOLD in Q4 2025 and has held it in 2 quarters since. The position peaked at $12.4M in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Versor Investments held 136,069 shares of Amicus Therapeutics worth $1.97M as of Q1 2026.
  • Versor Investments sold 735,165 Amicus Therapeutics shares in Q1 2026, an estimated $10.5M.
  • Amicus Therapeutics made up 4.82% of Versor Investments's portfolio in Q1 2026, its #7 holding.
  • Versor Investments first reported a position in Amicus Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Versor Investments's Amicus Therapeutics position peaked at $12.4M in Q4 2025.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Versor Investments's 13F filing for Q1 2026, filed 12 May 2026.